CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: April 5, 2021
Result type: Reports
Project Number: SR0687-000
Product Line: Reimbursement Review

Generic Name: natalizumab

Brand Name: Tysabri

Manufacturer: Biogen Canada, Inc.

Therapeutic Area: Multiple Sclerosis, relapsing-remitting

Indications: Tysabri (intravenous, IV; and subcutaneous, SC) is indicated as monotherapy for the treatment of patients with the relapsing-remitting form of multiple sclerosis (MS) to reduce the frequency of clinical exacerbations, to decrease the number and volume of active brain lesions identified on magnetic resonance imaging (MRI) scans and to delay the progression of physical disability. Tysabri is generally recommended in MS patients who have had an inadequate response to, or are unable to tolerate, other therapies for multiple sclerosis.

Manufacturer Requested Reimbursement Criteria1: Tysabri SC to be funded in similar manner as Tysabri IV.

Submission Type: Initial

Project Status: Pending

Call for patient/clinician input open: April 5, 2021

Call for patient/clinician input closed: May 14, 2021

Anticipated Date: April 21, 2021

Fee Schedule: Pending

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Submit Feedback